A Delaware-based health-technology company has issued a $1 convertible promissory note due December 12, 2026, featuring a 15% original issue discount and a 65% conversion price floor.

Key Highlights

  • The company issued a $1 convertible promissory note maturing December 12, 2026, with a 15% original issue discount.
  • The note includes a 65% conversion price floor tied to the lowest three-day volume-weighted average stock price.
  • Terms allow conversion only if equity conditions are met, including uninterrupted trading and sufficient authorized shares.
  • A change of control triggers mandatory repayment or conversion at the lower of the then-current conversion price or 65% of market value.
  • The securities were sold under an SEC exemption, prohibiting public resale without registration or a valid exemption.

A Delaware-registered health-technology firm has finalized a $1 convertible promissory note with a 15% original issue discount, maturing on December 12, 2026. The transaction, disclosed in an SEC filing under accession number 0001213900-26-068871, introduces a direct financial obligation that converts into common stock under predefined conditions.

The note’s conversion terms include a 65% floor price, calculated as the greater of the floor price or 65% of the lowest volume-weighted average price over the three trading days preceding conversion. This structure protects investors from extreme price declines while allowing participation in potential upside. Conversion is contingent on equity conditions, including uninterrupted stock trading, sufficient authorized shares, and the absence of material defaults or pending change-of-control transactions.

Investors face a beneficial ownership limitation, capping their stake to prevent triggering public reporting thresholds. The note also includes a mandatory default amount, accelerating repayment if certain events occur, such as bankruptcy or failure to honor conversion requests. A change of control, defined as a 50% or greater shift in voting power or a 51% reduction in pre-transaction shareholder ownership, triggers either mandatory repayment or conversion at the lower of the then-current price or 65% of market value.

The securities were issued under an exemption from SEC registration under the Securities Act of 1933, restricting resale unless registered or qualifying for another exemption. The company’s representative, David Ayanoglou, is designated to provide additional details upon request, including information required under Treasury Regulation §1.1275-3(b)(1).

Market observers note that such convertible notes are common in health-tech financing, offering companies access to capital while deferring dilution. However, the 15% discount and 65% floor may signal elevated risk or limited alternative funding options. The note’s terms also include a "buy-in" provision, allowing investors to purchase shares in the open market if the company fails to deliver conversion shares on time.

The transaction reflects broader trends in private health-tech financing, where convertible instruments remain a preferred tool for bridging capital needs without immediate equity dilution. Analysts will monitor whether the company meets its equity conditions, as failure could trigger default provisions or force renegotiation

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.